WO2003061652A8 - 3-(imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors - Google Patents

3-(imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors

Info

Publication number
WO2003061652A8
WO2003061652A8 PCT/IB2003/000060 IB0300060W WO03061652A8 WO 2003061652 A8 WO2003061652 A8 WO 2003061652A8 IB 0300060 W IB0300060 W IB 0300060W WO 03061652 A8 WO03061652 A8 WO 03061652A8
Authority
WO
WIPO (PCT)
Prior art keywords
imidazolyl
tafia inhibitors
alkoxypropanoic
acids
alkyl
Prior art date
Application number
PCT/IB2003/000060
Other languages
French (fr)
Other versions
WO2003061652A1 (en
Inventor
Charlotte Moira Norfo Allerton
David John Bull
Mark Edward Bunnage
Robert John Maguire
John Steele
Original Assignee
Pfizer Ltd
Charlotte Moira Norfo Allerton
David John Bull
Mark Edward Bunnage
Robert John Maguire
John Steele
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0201389A external-priority patent/GB0201389D0/en
Priority claimed from GB0202027A external-priority patent/GB0202027D0/en
Priority to EA200400716A priority Critical patent/EA200400716A1/en
Priority to MXPA04006573A priority patent/MXPA04006573A/en
Priority to JP2003561596A priority patent/JP2005520811A/en
Priority to APAP/P/2004/003084A priority patent/AP2004003084A0/en
Priority to EP03700059A priority patent/EP1467731A1/en
Priority to KR10-2004-7011370A priority patent/KR20040077775A/en
Application filed by Pfizer Ltd, Charlotte Moira Norfo Allerton, David John Bull, Mark Edward Bunnage, Robert John Maguire, John Steele, Pfizer filed Critical Pfizer Ltd
Priority to BR0307016-6A priority patent/BR0307016A/en
Priority to CA002472238A priority patent/CA2472238A1/en
Priority to IL16267703A priority patent/IL162677A0/en
Publication of WO2003061652A1 publication Critical patent/WO2003061652A1/en
Priority to IS7310A priority patent/IS7310A/en
Priority to TNP2004000121A priority patent/TNSN04121A1/en
Priority to HR20040659A priority patent/HRP20040659A2/en
Priority to NO20043457A priority patent/NO20043457L/en
Publication of WO2003061652A8 publication Critical patent/WO2003061652A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Compounds according to formula (I) wherein n is 0-3, R1 is optionally substituted C1-6 alkyl, C2-6 alkenyl, or C2-6 alkynyl, Heterocycle, Aromatic heterocycle, Aryl or hydrogen and R2, R3, R4, R5, R6, R7, R8 and R9 are each independently selected from hydrogen and optionally substituted C 1-6 alkyl, or R5 and R8 are an alkylene chain, are novel. They are useful in the treatment of thrombotic conditions and other pathologies associated with fibrin deposition.
PCT/IB2003/000060 2002-01-22 2003-01-10 3-(imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors WO2003061652A1 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
CA002472238A CA2472238A1 (en) 2002-01-22 2003-01-10 3-(imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors
IL16267703A IL162677A0 (en) 2002-01-22 2003-01-10 3-(Imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors
BR0307016-6A BR0307016A (en) 2002-01-22 2003-01-10 3- (imidazolyl) -2-alkoxypropanoic acids
JP2003561596A JP2005520811A (en) 2002-01-22 2003-01-10 3- (imidazolyl) -2-alkoxypropanoic acid as a TAFIa inhibitor
APAP/P/2004/003084A AP2004003084A0 (en) 2002-01-22 2003-01-10 3-(imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors
EP03700059A EP1467731A1 (en) 2002-01-22 2003-01-10 3-(imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors
KR10-2004-7011370A KR20040077775A (en) 2002-01-22 2003-01-10 3-(IMIDAZOLYL)-2-ALKOXYPROPANOIC ACIDS AS TAFIa INHIBITORS
EA200400716A EA200400716A1 (en) 2002-01-22 2003-01-10 3- (IMIDAZOLYL) -2-ALCOXYPROPIONIC ACIDS AS TAFIA INHIBITORS (THROMBIN-ACTIVATED FIBRINOLYSIS INHIBITOR)
MXPA04006573A MXPA04006573A (en) 2002-01-22 2003-01-10 3-(imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors.
IS7310A IS7310A (en) 2002-01-22 2004-06-14 3- (imidazolyl) -2-alkoxypropanoic acids which inhibit TAFIa
TNP2004000121A TNSN04121A1 (en) 2002-01-22 2004-06-30 Acides 3 - (imidazolyl) - 2 - alkoxypropanoiques servant d'inhibiteurs de tafia
HR20040659A HRP20040659A2 (en) 2002-01-22 2004-07-19 3-(imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors
NO20043457A NO20043457L (en) 2002-01-22 2004-08-19 3- (imidazolyl) -2-alkoxypropanoic acids as TAFIA inhibitors

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0201389A GB0201389D0 (en) 2002-01-22 2002-01-22 3-(imidazolyl)-2-alkoxypropanoic acids
GB0201389.4 2002-01-22
GB0202027.9 2002-01-29
GB0202027A GB0202027D0 (en) 2002-01-29 2002-01-29 3-(imidazolyl)-2-alkoxypropanoic acids

Publications (2)

Publication Number Publication Date
WO2003061652A1 WO2003061652A1 (en) 2003-07-31
WO2003061652A8 true WO2003061652A8 (en) 2004-09-10

Family

ID=27614792

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2003/000060 WO2003061652A1 (en) 2002-01-22 2003-01-10 3-(imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors

Country Status (24)

Country Link
EP (1) EP1467731A1 (en)
JP (1) JP2005520811A (en)
KR (1) KR20040077775A (en)
CN (1) CN1620291A (en)
AP (1) AP2004003084A0 (en)
AR (1) AR038197A1 (en)
BR (1) BR0307016A (en)
CA (1) CA2472238A1 (en)
EA (1) EA200400716A1 (en)
EC (1) ECSP045200A (en)
HR (1) HRP20040659A2 (en)
IL (1) IL162677A0 (en)
IS (1) IS7310A (en)
MA (1) MA27167A1 (en)
MX (1) MXPA04006573A (en)
NO (1) NO20043457L (en)
OA (1) OA12756A (en)
PA (1) PA8563501A1 (en)
PE (1) PE20030929A1 (en)
PL (1) PL371487A1 (en)
TN (1) TNSN04121A1 (en)
TW (1) TW200302094A (en)
UY (1) UY27615A1 (en)
WO (1) WO2003061652A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005051384A1 (en) * 2003-11-25 2005-06-09 Pfizer Limited Stabilised pharmaceutical compositions
JP2008536923A (en) * 2005-04-18 2008-09-11 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト Use of TAFI inhibitors to enhance myocardial reperfusion and facilitate PCI
EP2361910A4 (en) 2008-10-29 2012-08-01 Taisho Pharmaceutical Co Ltd Compound having tafia inhibitory activity
US8987242B2 (en) 2008-12-05 2015-03-24 Merck Sharp & Dohme Corp. Morpholinone compounds as factor IXA inhibitors
US8642582B2 (en) 2008-12-05 2014-02-04 Merck Sharp & Dohme Corp. Morpholinone compounds as factor IXa inhibitors
LT2548871T (en) * 2010-03-18 2017-09-25 Daiichi Sankyo Company, Limited Cycloalkyl-substituted imidazole derivative
CN102884053B (en) * 2010-03-18 2016-03-02 第一三共株式会社 Cyclopropanecarboxylacid acid derivative
CA2914533A1 (en) 2013-06-10 2014-12-18 Sanofi Macrocyclic urea derivatives as inhibitors of tafia, their preparation and their use as pharmaceuticals
EP3437641A4 (en) 2016-03-29 2019-11-20 Daiichi Sankyo Company, Limited Inflammatory intestinal disease therapeutic agent
TWI802591B (en) 2017-09-14 2023-05-21 日商第一三共股份有限公司 Compound having ring structures

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9901572D0 (en) * 1999-05-03 1999-05-03 Astra Ab New compounds
SK1732003A3 (en) * 2000-08-17 2004-08-03 Pfizer Substituted imidazoles as TAFIa inhibitors

Also Published As

Publication number Publication date
IL162677A0 (en) 2005-11-20
UY27615A1 (en) 2003-08-29
CN1620291A (en) 2005-05-25
CA2472238A1 (en) 2003-07-31
JP2005520811A (en) 2005-07-14
MA27167A1 (en) 2005-01-03
OA12756A (en) 2006-07-03
MXPA04006573A (en) 2004-10-04
NO20043457L (en) 2004-08-19
WO2003061652A1 (en) 2003-07-31
ECSP045200A (en) 2004-08-27
IS7310A (en) 2004-06-14
HRP20040659A2 (en) 2004-10-31
TNSN04121A1 (en) 2006-06-01
AR038197A1 (en) 2005-01-05
KR20040077775A (en) 2004-09-06
PA8563501A1 (en) 2004-08-31
PL371487A1 (en) 2005-06-13
EA200400716A1 (en) 2004-12-30
EP1467731A1 (en) 2004-10-20
TW200302094A (en) 2003-08-01
AP2004003084A0 (en) 2004-09-30
BR0307016A (en) 2004-11-03
PE20030929A1 (en) 2003-11-05

Similar Documents

Publication Publication Date Title
NO20064418L (en) Novel amido-substituted hydroxy-6-phenylphenanthridines
EA200600509A1 (en) COMPOUNDS OF PYRIMIDOTHIOPHENE
NO20062950L (en) 5,7-diaminopyrazolo-43-Dlpyrimidines with PDE-5 inhibitory activity
EA200601830A1 (en) ORT-SUBSTITUTED ARYL OR HETEROARYL AMIDAL COMPOUNDS
BR0313330A (en) Pyrrolidinedione-substituted piperidine-phthalazones as pde4 inhibitors
CA2378183A1 (en) Antibacterial heterobicyclic substituted phenyl oxazolidinones
IN2012DN00758A (en)
DK1265606T3 (en) cell adhesion inhibitors
NO20081797L (en) New solfonyl pyrrols as inhibitors of HDAC
NO20076006L (en) acetylene Derivatives
NO20064351L (en) Caspase Inhibitors and Uses thereof
NO331012B1 (en) N-sulfonyl-4-methyleneamino-3-hydroxy-2-pyridones as antimicrobial agents
DK1709044T4 (en) Oxazolidinone-quinolone hybrid antibiotics
MXPA04005940A (en) 3-(imidazolyl)-2-aminopropanoic acids for use as tafi-a inhibitors for the treatment of thrombotic diseases.
DE602004011255D1 (en) PHOSPHINIC ACID DERIVATIVES, INHIBITORS OF BETA-SEKRETASE FOR THE TREATMENT OF ALZHEIMER DISEASE
WO2003061652A8 (en) 3-(imidazolyl)-2-alkoxypropanoic acids as tafia inhibitors
NO20063220L (en) Tricyclic imidazopyridines for use as gastric secretion inhibitors
NO20080144L (en) Spiro-benzimidazoles as inhibitors of gastric acid and secretion
NO20062307L (en) Spirofuropyridinarylderivater
MX2007001952A (en) Compounds and compositions useful as cathepsin s inhibitors.
DK1899331T3 (en) Homomorpholinoxazolidones as antibacterial agents
TW200612944A (en) 4-(2,4-dichloro-5-methoxyphenyl)amino-6-methoxy-7-{[5-(substituted-amino)methyl]-3-furyl}-3-quinolinecarbonitriles as kinase inhibitors
UA86616C2 (en) Novel carboxamides for use as xa inhibitors
MY121785A (en) Hydroxamic acid derivatives as inhibitors of the production of soluble cd23
ATE275558T1 (en) 4-ARYLPIPERIDINE DERIVATIVES FOR THE TREATMENT OF PRURITUS

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1734/DELNP/2004

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 162677

Country of ref document: IL

Ref document number: 200400716

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: P-575/04

Country of ref document: YU

WWE Wipo information: entry into national phase

Ref document number: 2003237012

Country of ref document: AU

Ref document number: 2472238

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/006573

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2004/05344

Country of ref document: ZA

Ref document number: 200405344

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2003700059

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 534068

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: AP/P/2004/003084

Country of ref document: AP

WWE Wipo information: entry into national phase

Ref document number: P20040659A

Country of ref document: HR

WWE Wipo information: entry into national phase

Ref document number: 1-2004-501093

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 8329

Country of ref document: GE

Ref document number: 5666

Country of ref document: GE

Ref document number: 2003561596

Country of ref document: JP

Ref document number: 2003802599X

Country of ref document: CN

Ref document number: 1020047011370

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1200400802

Country of ref document: VN

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 31/2003 UNDER (72, 75) REPLACE "MAGUIRE, ROBERT, JOHN ¢GB/GB!; PFIZER GLOBAL RESEARCH AND DEVELOPMENT, RAMSGATE ROAD, SANDWICH, KENT CT13 9NJ (GB)" BY "MAGUIRE, ROBERT, JOHN ¢GB/US!; PFIZER GLOBAL RESEARCH AND DEVELOPMENT, EASTERN POINT ROAD, GROTON, CT 06340 (US)"

WWP Wipo information: published in national office

Ref document number: 2003700059

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2003700059

Country of ref document: EP